Clinical Manifestations, Laboratory Findings and Disease Course of Iranian Pediatric Patients Diagnosed with Hepatitis A Infection

  • Mozhgan Zahmatkeshan, Department of pediatrics, Shiraz University of Medical Sciences, Shiraz, Iran
  • khadijesadat Najib Department of pediatrics, Shiraz University of Medical Sciences, Shiraz, Iran
  • Arezoo Abolhasanbeigi Student research committee, Shiraz University of Medical Sciences, Shiraz, Iran
Keywords: hepatitis A, Clinical manifestation, Laboratory findings, Children


Background: According to some provincial reports, prevalence of hepatitis A has had a decreasing trend during the past decade in Iran. We aimed to overview clinical manifestations and laboratory findings of Iranian pediatric patients diagnosed with hepatitis A infection. Materials and Methods: This retrospective study was performed on 162 consecutive pediatric cases of hepatitis A infection. Data were collected by reviewing hospital records on admission to hospital. Results: The mean±SD age of participants was 9.90±4.08 years and 55.6% were boys. Regarding clinical manifestations, the most frequent symptom was jaundice. Fever was more prevalent in girls than in boys; whereas, abdominal tenderness was more prevalent in boys compared to girls. There was no difference in the prevalence of other clinical indices as well as in laboratory parameters between two sexes. Diarrhea was significantly more frequent in children younger than 2 years compared with other age subgroups. However, abdominal tenderness was more frequent in older patients compared to younger children. Regarding laboratory parameters, except for serum direct bilirubin that raised less in children younger than 2 years, the prevalence of other biochemical markers abnormality was comparable in different age groups. Conclusion: Hepatitis A infection is a common finding among Iranian children that equally occurs in boys and girls, while commonly appearing in children aged 7-18 years. The most frequent abnormal changes in laboratory parameters refer to change of liver enzymes, serum bilirubin, serum albumin and coagulated indices. [GMJ.2015;4(2):90-95]


Jacobsen KH, Wiersma ST. Hepatitis A virus seroprevalence by age and world region, 1990 and 2005. Vaccine 2010;28(41): 6653-7.

Ceyhan M, Yildirim I, Kurt N, Uysal G, Dikici B, Ecevit C, et al. Differences in hepatitis A seroprevalence among geographical regions in Turkey: a need for regional vaccination recommendations. J Viral Hepat 2008 15 Suppl 2: 69-72.

Wasley A, Fiore A, Bell BP. Hepatitis A in the era of vaccination. Epidemiol Rev. 2006;28:101–11.

Taylor RM, Davern T, Munoz S, Han S-H, McGuire B, Larson AM et al. Fulminant Hepatitis A Virus Infection in the United States: Incidence, Prognosis, and Outcomes. Hepatology. 2006;44(6):1589-97.

Tosti ME, Spada E, Romano L, Zanetti A, Mele A. Acute hepatitis A in Italy: incidence, risk factors and preventive measures. J Viral Hepat. 2008;15Suppl 2:26–32.

Jacobsen KH, Koopman JS. Declining hepatitis A seroprevalence: a global review and analysis. Epidemiol Infect. 2004;132(6):1005–22.

Payne L, Coulombier D. Hepatitis A in the European Union: responding to challenges related to new epidemiological patterns. Euro Surveill. 2009;14(3):1–2.

Castkova J, Benes C. Increase in hepatitis A cases in the Czech Republic in 2008—an update. Euro Surveill.2009;14(3):1–3.

Staes CJ, Schlenker TL, Risk I, Cannon KG, Harris H, PaviaAT, et al. Sources of infection among persons with acute hepatitis A and no identified risk factors during a sustained community-wide outbreak. Pediatrics. 2000;106(4):E54.

D’Argenio P, Adamo B, Cirrincione R, Gallo G. The role of vaccine in controlling hepatitis A epidemics.Vaccine.2003;21(19–20):2246–9.

Kohl I, Nemecek V, Summerova M, Chlibek R, Nad’ova K, Minarikova O. Long-term protective effect of post-exposure Havrix administration during viral hepatitis Type A outbreaks. Eur J Epidemiol. 2006;21(12):893–9.

Hanif M, Raza J, Qureshi H, Issani Z. Etiology of chronic liver disease in children. J Pak Med Assoc. 2004;54(3):119-22.

Ciocca M. Clinical course and consequences of hepatitis A infection. Vaccine 2000;18 (Suppl 1): 71-4.

Kara A, Parlakay AÖ, Akan A, Cengiz AB, Ceyhan M. Symptomatic Hepatitis A and Cholestatic Hepatitis as A Complication of Hepatitis A. J Pediatr Inf 2009; 3(4):165-7.

Çetinkaya B, Tezer H, ÖzkayaParlakay A, RevideSaylı T. Evaluation of pediatric patients with hepatitis A. J Infect DevCtries 2014; 8(3):326-30.

Franco E, Meleleo C, Serino L, Sorbara D, Zaratti L. Hepatitis A: Epidemiology and prevention in developing countries. World J Hepatol 2010; 4(3): 68-73.

Victor JC, Surdina TY, Suleimenova SZ, Favorov MO, Bell BP, Monto AS. Person-to-person transmission of hepatitis A virus in an urban area of intermediate endemicity: implications for vaccination strategies. Am J Epidemiol. 2006;163(3):204-10.

Campagna M, Siddu A, Meloni A, Basciu C, Ferrai L, Pettinau A et al. Changing Pattern of Hepatitis A Virus Epidemiology in an Area of High Endemicity. Hepat Mon. 2012;12(6):382-5.

Jeong SH, Lee HS. Hepatitis A: clinical manifestations and management. Intervirology. 2010;53(1):15-9.

Stephen MF, Ian DG. Hepatitis A Virus (2000) In: Mandell GL, Bennett JE, Dolin R, editors. Principles and Practice of Infectious Disease.ChurchillLivingstones, New York 1920-1940.

Koff RS. Hepatitis A. Lancet. 1998;351(9116):1643–9.

How to Cite
Zahmatkeshan, M., Najib, khadijesadat, & Abolhasanbeigi, A. (2015). Clinical Manifestations, Laboratory Findings and Disease Course of Iranian Pediatric Patients Diagnosed with Hepatitis A Infection. Galen Medical Journal, 4(2), 90-95.
Original Article